Russell Investments Group Ltd. Trims Holdings in Encompass Health Co. (NYSE:EHC)

Russell Investments Group Ltd. decreased its position in Encompass Health Co. (NYSE:EHC - Free Report) by 9.2% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 207,283 shares of the company's stock after selling 20,938 shares during the period. Russell Investments Group Ltd. owned about 0.21% of Encompass Health worth $13,830,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of the company. McGlone Suttner Wealth Management Inc. bought a new position in shares of Encompass Health in the 4th quarter valued at about $30,000. GAMMA Investing LLC acquired a new position in shares of Encompass Health during the 4th quarter worth approximately $33,000. C M Bidwell & Associates Ltd. bought a new stake in shares of Encompass Health during the 3rd quarter worth approximately $35,000. Headlands Technologies LLC bought a new stake in shares of Encompass Health during the 4th quarter worth approximately $70,000. Finally, Harvest Fund Management Co. Ltd bought a new position in shares of Encompass Health in the third quarter valued at $109,000. Institutional investors and hedge funds own 97.25% of the company's stock.

Insider Activity at Encompass Health

In related news, CEO Mark J. Tarr sold 44,976 shares of the stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $83.27, for a total value of $3,745,151.52. Following the completion of the transaction, the chief executive officer now owns 554,098 shares of the company's stock, valued at approximately $46,139,740.46. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 2.10% of the stock is currently owned by insiders.

Encompass Health Price Performance

NYSE:EHC traded down $0.21 during mid-day trading on Friday, reaching $83.21. The stock had a trading volume of 601,904 shares, compared to its average volume of 716,039. Encompass Health Co. has a 12 month low of $57.55 and a 12 month high of $85.84. The stock has a market capitalization of $8.33 billion, a PE ratio of 22.49, a P/E/G ratio of 1.30 and a beta of 0.92. The company has a debt-to-equity ratio of 1.14, a current ratio of 1.37 and a quick ratio of 1.28. The stock has a 50-day simple moving average of $79.15 and a two-hundred day simple moving average of $71.55.

Encompass Health (NYSE:EHC - Get Free Report) last issued its quarterly earnings results on Wednesday, April 24th. The company reported $1.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.93 by $0.19. Encompass Health had a return on equity of 18.01% and a net margin of 7.60%. The company had revenue of $1.32 billion for the quarter, compared to analyst estimates of $1.27 billion. During the same quarter last year, the company posted $0.88 EPS. The company's revenue for the quarter was up 13.4% compared to the same quarter last year. On average, equities analysts anticipate that Encompass Health Co. will post 4.1 earnings per share for the current year.

Encompass Health Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, July 15th. Stockholders of record on Monday, July 1st will be paid a $0.15 dividend. The ex-dividend date is Friday, June 28th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.72%. Encompass Health's payout ratio is currently 16.22%.

Analyst Ratings Changes

EHC has been the topic of several analyst reports. Truist Financial upped their price target on shares of Encompass Health from $82.00 to $86.00 and gave the stock a "buy" rating in a research report on Friday, February 9th. Barclays raised their price target on Encompass Health from $101.00 to $108.00 and gave the company an "overweight" rating in a report on Thursday, April 25th. Stephens restated an "overweight" rating and set a $85.00 price objective on shares of Encompass Health in a report on Tuesday, January 16th. Royal Bank of Canada reiterated an "outperform" rating and set a $83.00 target price on shares of Encompass Health in a research note on Friday, February 9th. Finally, Mizuho boosted their price target on Encompass Health from $93.00 to $95.00 and gave the company a "buy" rating in a research note on Thursday, April 25th. Eight research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Encompass Health has an average rating of "Buy" and a consensus target price of $90.29.

Encompass Health Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.